Although not yet standard in fibrosarcoma, further targeting neural-tumor interactions (e.g., anti-NGF therapies, β-blockers, Trk inhibitors) is a growing area of interest in oncology and represent a promising frontier in cancer treatment, offering novel avenues to disrupt tumor-supportive neural signaling and reshape the tumor microenvironment [7]. This evidence concerns the gene NGF and neoplasm.